Search Science Hub

Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

AASLD 2026 5 - 9 November 2026

Effects of zalfermin, cagrilintide, and semaglutide on non-invasive fibrosis biomarkers in alcohol-related liver disease: A phase 2 randomized trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

MASH

Congress oral presentation

GLP-1 RA

Semaglutide

PHASE 2 (RCT)

Search Science Hub

Are you a healthcare professional?

Effects of zalfermin, cagrilintide, and semaglutide on non-invasive fibrosis biomarkers in alcohol-related liver disease: ​A phase 2 randomized trial

Effects of zalfermin, cagrilintide, and semaglutide on non-invasive fibrosis biomarkers in alcohol-related liver disease: A phase 2 randomized trial